Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. (FULC): 3 pipeline candidates · ~22 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
21.9 months
D/E 0.04 · 14% dilution
Lead: Phase 3
3 candidates
N/A
0 buys · 2 sells (180d)
A transparent, data-derived signal for Fulcrum Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$233.9M
Cash
$50.3M
Quarterly Burn
$18.8M
Runway
21.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| ftx-6274 | Preclinical |
| losmapimod | Phase 3 |
| pociredir | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
163
Total value held
$451.4M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 6,561,111 | $50.3M |
| ra capital management, l.p. | 6,053,960 | $46.4M |
| blackrock, inc. | 5,390,593 | $41.3M |
| vanguard capital management llc | 5,385,896 | $41.3M |
| braidwell lp | 3,134,922 | $24.0M |
| balyasny asset management l.p. | 2,179,946 | $16.7M |
| point72 asset management, l.p. | 2,074,855 | $15.9M |
| gsk plc | 1,785,714 | $13.7M |
| jones hill capital lp | 1,771,926 | $13.6M |
| d. e. shaw & co., inc. | 1,623,281 | $12.5M |
Showing top 10 of 163 institutional holders of Fulcrum Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Fulcrum Therapeutics, Inc.'s pipeline?
Fulcrum Therapeutics, Inc. (FULC) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Fulcrum Therapeutics, Inc.'s lead drug candidate?
Fulcrum Therapeutics, Inc.'s most advanced tracked candidate is ftx-6274 (Preclinical) for prostate cancer.
What is Fulcrum Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Fulcrum Therapeutics, Inc. has approximately 21.9 months of cash runway.
What is Fulcrum Therapeutics, Inc.'s market capitalization?
Fulcrum Therapeutics, Inc.'s market capitalization is approximately $233.9M.
Who is the CEO of Fulcrum Therapeutics, Inc.?
Mr. Alexander C. Sapir is the chief executive officer of Fulcrum Therapeutics, Inc. (FULC).
Get the full picture on Fulcrum Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.